Gilead Sciences, Inc. (GILD) Shares Bought by Intact Investment Management Inc.

Intact Investment Management Inc. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 115.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,000 shares of the biopharmaceutical company’s stock after purchasing an additional 54,600 shares during the period. Intact Investment Management Inc.’s holdings in Gilead Sciences were worth $7,875,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Spectrum Asset Management Inc. NB CA boosted its holdings in Gilead Sciences by 795.9% in the third quarter. Spectrum Asset Management Inc. NB CA now owns 25,299 shares of the biopharmaceutical company’s stock worth $1,953,000 after acquiring an additional 22,475 shares in the last quarter. Beck Mack & Oliver LLC boosted its holdings in Gilead Sciences by 1.7% in the third quarter. Beck Mack & Oliver LLC now owns 402,492 shares of the biopharmaceutical company’s stock worth $31,076,000 after acquiring an additional 6,876 shares in the last quarter. CWM LLC boosted its holdings in Gilead Sciences by 54.5% in the third quarter. CWM LLC now owns 61,200 shares of the biopharmaceutical company’s stock worth $4,725,000 after acquiring an additional 21,601 shares in the last quarter. Bell Asset Management Ltd boosted its holdings in Gilead Sciences by 7.8% in the third quarter. Bell Asset Management Ltd now owns 58,301 shares of the biopharmaceutical company’s stock worth $4,501,000 after acquiring an additional 4,209 shares in the last quarter. Finally, Oppenheimer & Co. Inc. boosted its holdings in Gilead Sciences by 0.5% in the third quarter. Oppenheimer & Co. Inc. now owns 415,155 shares of the biopharmaceutical company’s stock worth $32,055,000 after acquiring an additional 1,984 shares in the last quarter. Institutional investors own 78.23% of the company’s stock.

GILD stock opened at $70.90 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.36, a quick ratio of 3.39 and a current ratio of 3.47. The company has a market capitalization of $90.41 billion, a PE ratio of 8.28, a P/E/G ratio of -3.52 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The company had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter last year, the company earned $2.27 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be issued a $0.57 dividend. The ex-dividend date of this dividend is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.22%. Gilead Sciences’s dividend payout ratio is presently 26.64%.

Several brokerages have issued reports on GILD. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. ValuEngine lowered Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, August 20th. Mizuho set a $94.00 price target on Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday, July 31st. Zacks Investment Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 25th. Finally, Cantor Fitzgerald increased their price target on Gilead Sciences from $87.00 to $88.00 and gave the stock an “overweight” rating in a report on Friday. Thirteen investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $87.84.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 150,000 shares of company stock worth $11,502,500 in the last 90 days. Corporate insiders own 1.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Article: Balanced Fund

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply